Evolus, Inc. has a 1 year low of $6.51 and a 1 year high of $14.34.

Source: https://www.etfdailynews.com/2023/02/25/new-york-state-common-retirement-fund-purchases-3940-shares-of-evolus-inc-nasdaqeols/

HC Wainwright restated a “buy” rating on shares of Evolus in a report on Wednesday, November 9th.

Source: https://www.etfdailynews.com/2023/02/25/new-york-state-common-retirement-fund-purchases-3940-shares-of-evolus-inc-nasdaqeols/

I remain optimistic on Evolus' prospects in the rapidly growing U.S. neurotoxin market, particularly among younger, aesthetically-oriented consumers.

Source: https://seekingalpha.com/article/4594928-evolus-capitalizing-on-the-growth-of-aesthetics-market?source=feed_all_articles